From the publishers of JADPRO

MPN Resource Center


Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

Last Updated: Thursday, June 29, 2023

According to data from the randomized, phase II MAJIC-PV trial comparing ruxolitinib versus best available therapy (BAT) in patients with polycythemia vera resistant/intolerant to hydroxycarbamide, duration of complete response (CR) was superior for the ruxolitinib arm (HR, 0.38; 95% CI, 0.24-0.61; P < .001). Event-free survival was superior for patients with a CR within 1 year (HR, 0.41; 95% CI, 0.21-0.78; P = .01), as well as for those on ruxolitinib (HR, 0.58; 95% CI, 0.35-0.94; P = .03). Patients treated with ruxolitinib more frequently achieved a molecular response, and molecular response was associated with improved outcomes (PFS: P = .001; EFS: P = .001; OS: P = .01).

Journal of Clinical Oncology
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study